In pulmonary arterial hypertension (PAH), right ventricular (RV) adaptation is essential to overcome the chronic increases in RV pressure overload. Ultimately, RV compensatory mechanisms are not sufficient and patients succumb to RV failure. The processes underlying the transition of RV adaptation to RV failure are not well understood. In this review, we propose that important insights in RV adaptation processes can be obtained by comparing different etiologies of PAH, namely patients with PAH secondary to Eisenmenger syndrome, patients with PAH secondary to systemic sclerosis and patients where no cause is identified: idiopathic PAH. Although the amount of RV afterload does not differ between these patient groups, their prognosis is distinctly different. We will show that an adaptive RV phenotype, as is observed in Eisenmenger patients, coincides with RV hypertrophy, increased RV contractility, low RV fibrosis and low RV diastolic stiffness. Whereas a phenotype of RV failure, as is observed in patients with PAH-secondary to systemic sclerosis, is characterized by impaired contractile reserve, RV fibrosis and RV diastolic stiffness.
Introduction
The first systematic explanation of the cardiopulmonary circulation was provided by the Roman scientist and philosopher Galen in the second century AD. He claimed that the liver-produced blood would flow into the right ventricle (RV), where it would move directly to the left ventricle (LV) via invisible holes in the interventricular septum. After that, the blood would flow to the local tissue in need, where it would disappear. 1, 2 Despite the discovery of Ibn al-Nafis in the 13th century that blood from the RV passes through the lungs before returning to the LV, Galen's theory dominated and influenced Western medical science for 15 centuries. 3 In 1628, William Harvey published his 'Exercitatio
Anatomica de Motu Cordis et Sanguinis in Animalibus'
, where he was the first to describe the importance of RV function by arguing; 'If Nature does nothing in vain, she would not have added the RV for the sole purpose of nourishing the lungs, but to propel blood through the lungs into the cavity of the LV'. 2 Ever since, significant progress has been made in understanding the RV, both in physiological and pathophysiological circumstances. In recent years, it has become clear that RV function is a significant determinant of prognosis and symptomatology in many cardiovascular diseases such as left-sided heart failure, congenital heart disease or pulmonary arterial hypertension (PAH). 4, 5 Therefore, understanding the RV has become increasingly relevant to researchers and clinicians alike. In PAH, RV afterload increases due to progressive remodelling and proliferation of the pulmonary vasculature. Even though RV adaptation mechanisms initially suffice; the progressive increases in pressureoverload leads almost inevitably to RV failure and death. 6 Except for lung transplantation, no curative treatment is available. Currently available vasodilators can only achieve a partial afterload reduction, but typically not enough to prevent RV failure, leading to an unsatisfactory median survival of 7 years. 7 Interestingly, there is a wide heterogeneity in the time between RV adaptation to RV failure, which is independent of the pressure-overload. 8 This observation suggests that the response of the RV rather than the amount of pressure-overload defines the fate of the RV in PAH. In aortic stenosis (AS), the LV equivalent of a chronic pressure overloaded ventricle, mechanisms underlying the conversion of LV adaptation towards LV failure have been more robustly studied. [9] [10] [11] [12] [13] [14] [15] However, despite the apparent resemblances between chronic RV and LV pressure overload, it is important to remember the relative increase in pressure overload is roughly two times higher in PAH than in AS. Additionally, while in both situations the ventricles adapt by increasing their mass, only the LV succeeds in normalizing the wall stress. [16] [17] [18] For these reasons and others, processes known to play a role in the transition from LV adaptation to LV failure can not necessarily be extrapolated to the RV. In this review, we will provide a perspective on the mechanisms of RV adaptation in PAH and discuss which mechanisms play a role in the transition from RV adaptation to right heart failure.
Possible mechanisms underlying transition of RV adaptation to RV failure
To preserve cardiac output and thus systolic function in PAH, the RV initially adapts by increasing its contractility via the enhancement of intrinsic contractile properties and via muscular hypertrophy. 19, 20 However, as the load progressively increases, the hypertrophic response will be hampered and a vicious cycle of RV dilatation, RV systolic and diastolic dysfunction ensues. 16, [20] [21] [22] Although it is unknown what triggers the transition from an adaptive to maladaptive state, several mechanisms that could play a role have been proposed including (i) genetic factors, (ii) neurohormonal overactivation and (iii) RV ischaemia ( Figure 1 ).
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Genetics
The BMPR2-mutation
The most common genetic cause of PAH are loss-of-function mutations in the Bone Morphogenetic Protein Receptor type 2 (BMPR2) gene.
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The BMPR2 receptor is a member of the transforming growth factor b (TGF-b) superfamily, and mutations have been shown to result in a disturbed TGF-b/BMP balance. Also less common genetic causes of PAH have their origin in the TGF-b superfamily (mutations in the activin receptor-like kinase 1, BMPR1B, caveolin-1, and SMAD9). [28] [29] [30] In the pulmonary vasculature, the over-activity of the TGF-b signalling leads to intimal hyperplasia, smooth muscle cell proliferation and apoptosis resistance. [31] [32] [33] [34] From a clinical perspective, it is known that patients with a BMPR2 mutation present at a younger age, with more severe haemodynamic derangements. 35 Most importantly, BMPR2 mutation carriers carry a worse prognosis-either dying at a younger age or requiring earlier lung transplantation, as elegantly shown in a recent meta-analysis by Evans and coworkers. 36 In addition, the authors conclude more severe RV dysfunction in BMPR2 mutated patients is responsible for the disparate outcomes. Other clinical studies have also revealed advanced RV dysfunction (as measured by stroke work index, stroke volume and cardiac index) at time of diagnosis in BMPR2 mutation carriers. 35, 37, 38 Most convincingly, a recent study found that BMPR2 mutation carriers have a reduced RV ejection fraction compared with patients without a BMPR2 mutation, both at baseline and after PAH-specific therapy, despite similar RV afterload. 39 This points towards an important role of the TGF-b/BMP balance in RV adaptation during a chronic pressure-overload. In the heart, the BMPR2 receptor is expressed by cardiomyocytes and the ventricular endocardium. [40] [41] [42] Signalling is activated to modulate angiogenic activity, cell growth, cell behaviour and survival. [41] [42] [43] [44] However, the cause of BMPR2 mutation-induced maladaptive RVremodelling is still unknown. From left heart failure, it is known that TGF-b overactivation in pressure-overloaded hearts directly lead to maladaptive hypertrophy, fibrosis, and hypertrophy. [45] [46] [47] [48] Although LV and RV pressure-overload are distinctly different as discussed earlier, Megalou et al. 49 demonstrated in a monocrotaline-induced PAHrat model that TGF-b blockage indeed attenuated PAH by both lowering RV afterload and improving RV function. Moreover, Hemnes et al. 50 has shown in multiple experimental models that the BMPR2 mutation can result in a disturbed hypertrophic response. These data suggest that the complex cardiac metabolic program of fatty acid oxidation and glycolysis is impaired in PAH, evident from lipid accumulation and RV lipotoxicity. [50] [51] [52] By comparing human RV tissue of healthy controls and PAH patients with and without BMPR2 mutation, our group observed increased mRNA levels of both the glycolysis and fatty acid oxidation pathway in PAH-patients without BMPR2 mutation. This might suggest that an impaired metabolic compensatory mechanism plays a role in the maladaptive hypertrophic response in the BMPR2. In addition, we were able to demonstrate that PAH-patients independent of their BMPR2 mutation status, both show signs of cardiac fibrosis, inflammation and angiogenic alterations in terms of capillary density. No differences were seen between BMPR2 mutation carriers and non-carriers. 39 
Neurohormonal activation
As a response to the chronic pressure-overload in PAH neurohormonal systems are activated, in particular the sympathetic and renin angiotensin aldosterone system (RAAS). [53] [54] [55] Although important for maintaining cardiac output via the enhancement of contractility and hypertrophy in Figure 1 Summary of the proposed pathophysiological mechanisms contributing to the transition of RV adaptation to RV failure. RV adaptation to the increased pressure overload occurs in patients with Eisenmenger Syndrome by adaptive RV hypertrophy. 103 In patients with idiopathic PAH, RV hypertrophy is not sufficient to cope with the increased pressure overload, and ischaemia [79] [80] [81] the short term, autonomic dysregulation might be a key player in transition of RV adaptation to RV failure in PAH. 56 
Sympathetic nervous system
Although it still has to be clarified when in the course of PAH sympathetic overstimulation in the RV begins, it has been shown that increased sympathetic activity is associated with a reduced chronotropic response to exercise, a delayed heart rate recovery and an increased mortality. 57, 58 In 1986, Bristow et al. 53 showed reduced b 1 -adrenoreceptor density in the PAH-patients. Later, this finding was confirmed an experimental study of Piao et al., 59 where the authors demonstrate a downregulation of mRNA and protein expression of the adrenergic receptors in a sugen-hypoxia and pulmonary artery banding model. As a consequence, less protein kinase A (PKA) will be activated through the binding of norepinephrine to the b 1 -adrenoreceptor, resulting in less PKA-mediated phosphorylation of key proteins involved in calcium handling and myofilament function. 60 As a result, increased diastolic stiffness in the RV of PAH-patients is observed due to interstitial and perivascular fibrosis as well as stiffening of the RV cardiomyocyte caused by hypophosphorylation of titin. 21 In experimental studies a (partial) restoration of the sympathetic overdrive by beta-blocker therapy led to a survival benefit as well as improved systolic and diastolic RV function, by restoring PKA-signaling. 61, 62 Despite the common use in left heart failure treatment, the PAH field has been reluctant to study the therapeutic potential of b-blocker therapy in patients because of the potential negative inotropic effects and further impairment of exercise capacity. 63, 64 In recent years, several retrospective studies reported no detrimental effects of b-blockage in terms of haemodynamics, clinical and functional outcomes, paving the way for a prospective randomized controlled trials assessing the safety and efficacy of b-blockers in PAH. 65, 66 Explorative studies enrolling relatively small numbers of PAH-patients show trends towards better cardiac function yet mixed results in terms of exercise tolerance and haemodynamic improvements.
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Parasympathetic activity
Sympathetic nerve system activity is closely related to parasympathetic activity, in such a way that increased activity in one will result in reduced activity in the other. Little data exist about the contribution of parasympathetic activity in PAH-induced right heart failure.
In PAH-patients reduced heart rate recovery, a marker of parasympathetic activity, is a strong predictor of prognosis and is associated with reduced exercise capacity. 69, 70 Although not well studied in PAH, targeting impaired parasympathetic signaling in left heart failure is beneficial, with previous studies showing improvement in LV function and survival after applying electric vagal stimulation and acetylcholinesterase inhibitors. [71] [72] [73] In addition, preliminary data of our own group demonstrate 
RAAS-system
Increases in RV wall stress and RV dysfunction lead to the release of renin secondary to chronically reductions in kidney perfusion. Consequently, the RAAS-system is constitutively activated in PAH and its degree of activation has been associated with disease progression and worse prognosis. 74 There is even some data to suggest that the pulmonary effects of RAAS-activation are even greater than the cardiac effects, and it has been demonstrated that several RAAS-inhibiting agents affect RV adaptation. 75 For example, chronic angiotensin II type 1-receptor blocker treatment restores RV-arterial coupling, RV dilatation and RV diastolic stiffness in a monocrotaline PAH-model. 74 In addition, renal denervation (affecting both the sympathetic and RAAS system) not only demonstrated improvement in haemodynamics, but also a significant reduction in RV fibrosis and diastolic stiffness. 76 Aldosterone inhibitors, which are currently a maintstay of therapy for symptomatic LV failure, have shown promise in RV failure due to PAH. 77 In retrospective cohort study combining an aldosterone-inhibitor with an endothelin-receptor antagonist lead to more significant improvements in functional status and cardiac function compared with endothelin-receptor antagonists alone. 78 The results of a large randomized controlled trial assessing the effects of aldosterone-inhibitor spironolactone treatment in PAHpatients are to be expected soon (Clinicaltrials.gov NCT01468571).
Ischaemia
A hallmark in the transition of RV adaptation to RV failure is the occurrence of capillary rarefaction. [79] [80] [81] In the pressure-overloaded RV, oxygen demand increases due to higher RV wall stress. To preserve the oxygen consumption/oxygen supply balance, the RV has to increase its myocardial efficiency and blood supply. Initially, these mechanisms are effective, as is proven by the fact that RV hypertrophy alone is not associated with worse survival. 82 However, at a certain point capillary density and myocardial efficiency decrease and the RV begins to fail. 81, 83 Ruiter et al. 81 demonstrated that despite similar capillaries per myocyte in PAH vs. controls, capillary density is actually less given the hypertrophied RV cardiomyocytes. Preserved capillary density is associated with hypoxia inducible factor 1 alpha (HIF-1a) and peroxisome proliferator activated receptor gamma co-activator alpha (PGC-a) encoding for vascular endothelial growth factor expression and therefore angiogenesis. As a consequence, HIF-1a-and PGC-1a-relatedcapillary angiogenesis are reduced in RV failure, but not in well adapted RV. 84 The loss of myocardial capillaries and loss of integrity in the remaining capillaries lead to microvascular RV dysfunction, apoptosis, and inflammation. A recent experimental study underlines the importance of the reduced capillary density in a maladapted pig model, where a mismatch between capillary density and workload was associated with increased myocardial fibrosis and worse RV failure. 85 An additional factor hampering myocardial blood supply in PAH patients may be reduced flow in the right coronary artery, a consequence of low systemic pressures, high RV pressures, and myocardial systolic compression. 86 Reduced flow is correlated to RV mass and RV systolic pressures, indicating more ischaemia as pressure afterload further increases. Although Brooks et al. showed a strong correlation between occlusion of the right coronary artery and RV contractility, the functional consequences in a chronic pressure-overload RV are still to be investigated. [87] [88] [89] [90] Taken this together, a reduced myocardial efficiency, reduced right coronary artery flow and capillary rarefaction occur during the transition from RV adaptation to RV failure.
What can we learn from the comparison of different etiologies of RV pressure overload?
Determining the relevance and causality of the above described pathophysiological mechanisms is difficult. Although there are several animal RV pressure overload: from hypertrophy to failure
models available which allow one to study the pathophysiological mechanisms in more detail, there are significant differences between the human and rodent heart and the difference in disease progression (human: years, rats: weeks) making it difficult to translate the results to the human applications. 91 In addition, mice are resistant to the development of severe PH and RV pressure overload, limiting the use of genetic mice models. In future, cardiac specific gene therapy in rats may provide a solution. 92 Ideally, a comparison of protein changes in RV biopsies at different stages of the disease would define the key pathomechanisms. However, due to the high trabeculation and the thickness of the RV free wall, the technical complexity in addition to the non-negligible risk of a ruptured RV free wall makes the procedure too challenging. 93 An alternative could be to obtain a biopsy of the interventricular septum at the side of the RV, assuming that wall tension is similar around the RV cavity. The wall tension of the RV free wall may differ from the tension in the interventricular septum, because of the structure of the RV. Therefore, cardiomyocytes from the interventricular septum may or may not be comparable to cardiomyocytes from the RV free wall. At least one study suggests that the gene expression of alpha-myosin heavy chain is expressed in all ventricular regions in non-failing human ventricular myocardium, signifying that biopsies of the interventricular septum could be used as a surrogate for the RV free wall. 94 However, a recent study in PAH-rats showed that important pathophysiological characteristics such as fibrosis, hypertrophy and capillary rarefaction may not be comparable between the RV free wall and RV septum. 95 Therefore, current tissue analysis is limited to the comparison of endstage disease. Nevertheless, important insights may be obtained when different etiologies of PAH are compared with each other, e.g. PAH where no cause is identified (idiopathic PAH), PAH secondary to systemic sclerosis and PAH secondary to Eisenmenger syndrome. Epidemiological studies show that these three etiologies of PAH differ significantly in prognosis. As is shown in Figure 2 , patients with PAH secondary to Eisenmenger syndrome have the best outcome with a 3-years survival of 85%, whereas this is only 63% in patients with idiopathic PAH and even worse in PAH-secondary to systemic sclerosis in which 3-years survival is only 52%. 96 Furthermore, data suggest that these survival differences cannot be described to the severity of the pulmonary vascular remodelling, but is most likely ascribed to differences in the RV response to pressure overload. 97, 98 The magnitude of RV pressure overload is similar among the groups, or even lower in the PAH-patients with systemic sclerosis, but the adaptation of the RV differs significantly. Therefore, these three PAH etiologies could be divided into three phenotypes of RV adaptation to increased pressure overload: (i). Eisenmenger patients represent a phenotype with RV adaptation; (ii) Patients with PAH-secondary to systemic sclerosis represents a phenotype of RV failure; (iii) idiopathic PAH-patients have a mixed phenotype of RV adaptation and RV failure.
Idiopathic PAH
When during clinical assessment no cause of pulmonary hypertension is found (such as left heart failure, pulmonary embolism, chronic obstructive pulmonary disease, etcetera), the diagnoses of idiopathic PAH is made. 99 The disease is further characterized by the relative young age of patients (average 49 years) and the female predominance (80%). 100 PAH is caused by excessive remodelling of the pulmonary vasculature, due to increased proliferation of the endothelial and smooth muscle cells of the small pulmonary arterioles. As a consequence of the pulmonary vascular remodelling, resistance in the pulmonary vasculature is increased resulting in elevated pulmonary artery pressure and pressure overload.
PAH secondary to systemic sclerosis
Systemic sclerosis is an autoimmune disorder which is characterized by increased inflammation and fibrosis formation in skin and visceral organs. Two forms of systemic sclerosis have been described: (i) Limited systemic sclerosis, in which the disease mainly affects the skin of the face, hands and feet, and; (ii) Diffuse systemic sclerosis, in which the disease also affects the visceral organs such as kidneys, heart, lungs and gastrointestinal tract. The prevalence of PAH in systemic sclerosis patients is estimated around 12%, and is more common in patients with limited systemic sclerosis than in patients with diffuse systemic sclerosis. 101 The development of PAH in systemic sclerosis has been ascribed to severe fibrotic and hypertrophic remodelling of the pulmonary arterioles. In addition, PAH is a principle cause of death in patients with systemic sclerosis.
PAH secondary to eisenmenger syndrome
Eisenmenger syndrome occurs in patients with a congenital heart defect, and is characterized by severe PAH with dilatation of the central pulmonary arterial, and reversal of a previous left-to-right shunt at the atrial and ventricular or aorta-pulmonary level. 102 Eisenmenger syndrome is mostly prevalent in patients with a shunt or defect distal to the tricuspid valve. Defects located proximal to the tricuspid valve include all atrial septum defects, sinus venosus defects and common atria, whereas posttricuspid defects include all ventricular septum defects, single ventricles and aortapulmonary communications. 103 Eisenmenger syndrome only occurs in patients with a large defect which is haemodynamically unrestrictive, indicating that there is no pressure difference from one side of Figure 2 Survival analyses of the three etiologies of pulmonary hypertension discussed in this review. Patients with PAH secondary to Eisenmenger syndrome have the best outcome with a 3-years survival of 85%, whereas this is only 63% in patients with idiopathic PAH and even worse in PAH-secondary to systemic sclerosis in which 3-years survival is only 52%. 96 Data suggest that these survival differences cannot be described to the severity of the pulmonary vascular remodelling, but is most likely ascribed to differences in the RV response to pressure overload. The magnitude of RV pressure overload is similar among the groups, or even lower in the PAH-patients with systemic sclerosis, but the adaptation of the RV differs significantly. Abbreviations: PAH, pulmonary arterial hypertension. the defect to the other. 104 The systemic level pulmonary artery pressure and increased pulmonary artery flow causes muscular hypertrophy of the small pulmonary arteries resulting in excessive pulmonary vascular remodelling.
RV hypertrophy
RV adaptation
As discussed earlier, one of the mechanisms of adaptation to an increased pressure overload of the RV is the induction of hypertrophy.
Although it has been suggested in several previous review papers that the RV in PAH-patients first adapt with concentric hypertrophy and eventually evolves into eccentric hypertrophy, this transition is difficult to prove due to the limitations of tissue collection. Indeed there is relatively little known about the kind of RV hypertrophy that is induced by increased pressure overload. The amount of RV hypertrophy has been compared between iPAHpatients, patients with PAH-secondary to systemic sclerosis and Eisenmenger patients by different imaging techniques. Interestingly, these analyses have revealed that the amount of hypertrophy between idiopathic PAH and PAH secondary to systemic sclerosis does not differ significantly. 105, 106 In contrast, in Eisenmenger patients RV hypertrophy is more pronounced, 98 despite similar pulmonary vascular remodelling and RV afterload in all three groups. This suggests that the adaptation of the RV to increased RV afterload is best in Eisenmenger patients in comparison to iPAH and PAH-secondary to systemic sclerosis ( Figure 3) . The heart of Eisenmenger patients (NB: post-tricuspid defects) is more comparable to a fetal heart than an adult heart. 103 Like in the fetal circulation in which pulmonary and systemic arterial pressures are equal because of the fetal ductus arteriosus, the heart of Eisenmenger patients has similar RV and LV free wall thickness and a flattened interventricular septum. In addition, whereas patients with other forms of PAH undergo regression of RV wall thickness during infancy, this does not occur in patients with Eisenmenger syndrome. Therefore, it has been hypothesized that the RV cardiomyocytes of Eisenmenger patients are 'primed' to endure the increased pressure overload. It is of utmost importance to unravel the molecular changes that are associated with the priming of the RV cardiomyocytes to endure prolonged RV pressure overload to enable the generation of therapeutic targets to induce a compensatory RV phenotype in other forms of PAH-induced right heart failure.
RV recovery
RV hypertrophy in patients with pulmonary hypertension is reversible. Studies before and after lung transplantation demonstrated that normalization of RV afterload results in normalization of RV mass. Whether intrinsic RV function is also restored remains to be established, though data from patients with chronic thromboembolic disease after effective pulmonary endarterectomy suggest the RV still may be impaired. 107, 108 Recent advancements with balloon pulmonary angioplasty in patients with chronic thrombo-embolic pulmonary hypertension allows to study the process of RV recovery following a decrease in RV afterload in the absence of interfering drugs in large number of patients. 109 
Intrinsic cardiomyocyte dysfunction
In addition to the size of the RV cardiomyocytes, intrinsic cardiomyocyte function is essential for the adaptation of the RV to increased pressure overload. RV pressure-volume analyses can give an indication on the load-independent alterations of RV function in PAH-patients. Because the original pressure-volume approaches of obtaining multiple pressure volume loops by temporary vena cava occlusions are not without risks in PAH-patients, alternative approaches have been developed during past years. Translating from work performed on the LV, Brimioulle et al. 110 described a single beat method to determine load-independent RV systolic function, which has been implemented in several clinical studies. 19, 21, [111] [112] [113] [114] A Valsalva manoeuvre to decrease pre-load, and more recently, external inferior vena cava pressure, have recently been used to generate multiple pressure-volume loops and asses load-independent systolic function in PAH-patients. 97, 105 It should be noted that the studies that we will discuss in the following paragraph, may differ on the techniques that were used to generate the information on load-independent RV systolic function. In patients with idiopathic PAH, an increase in RV contractility is observed in all patients independent of disease severity. 19 This is also confirmed on tissue level, in which we have determined force generation of RV cardiomyocyte from PAH-patients (both idiopathic PAH and Eisenmenger) in comparison to donors. RV cardiomyocytes of PAHpatients generated over the whole spectrum of calcium concentrations, more force than RV cardiomyocytes of donor hearts also after correction for differences in RV cardiomyocyte size. 21 Also a subgroup analyses was performed to compare idiopathic PAH and Eisenmenger patients, but no difference was observed, although it should be noted that the study was not powered for such an analyses. These measurements do not indicate whether the increase in RV contractility is sufficient to cope with the increase in RV pressure overload as is seen in PAH-patients. When RV contractility is corrected for the increase in RV afterload (RV-arterial coupling), we observed that the RV contractility increase is indeed insufficient to cope with the RV afterload in end-stage PAH-patients.
Interestingly, recent studies suggest that in patients with PAH secondary to systemic sclerosis the increase in RV contractility is absent (Figure 3) . Overbeek et al. 115 demonstrated that RV pump function was more affected in PAH-patients with systemic sclerosis in comparison to idiopathic PAH. In addition, also with pressure-volume analyses it was shown that RV contractility was reduced in PAH-patients with systemic with PAH secondary to systemic sclerosis and patients with PAH secondary to Eisenmenger syndrome. RV adaptation in patients with idiopathic PAH is characterized by increased RV hypertrophy, enhanced RV contractility, excessive RV fibrosis and RV diastolic stiffness. 21 RV adaptation in patients with PAH secondary to systemic sclerosis is comparable to idiopathic PAH except that patients with systemic sclerosis suffer from impaired RV contractility. 105 RV adaptation in patients with
Eisenmenger syndrome is more beneficial indicated by the lower amount of RV fibrosis and RV diastolic stiffness in comparison to patients with idiopathic PAH and PAH secondary to systemic sclerosis. 123 . RV pressure overload: from hypertrophy to failure sclerosis in comparison to idiopathic PAH, resulting in an abnormal RVarterial coupling. 97 More recently, preliminary data by Hsu and colleagues have extended this observation with RV cardiomyocyte measurements in which they confirmed the increased force generation of RV cardiomyocytes of idiopathic PAH-patients, which was absent in RV cardiomyocytes of patients with PAH-secondary to systemic sclerosis (Hsu S, et al. J Heart Lung Transplant 2017, abstract). There are several possible explanations for this discrepancy between idiopathic PAH and PAH secondary to systemic sclerosis including impaired calcium handling 105 or dysfunctional contractile machinery.
Additionally, differences in beta-adrenergic receptor signalling may also play a role. Although it has been demonstrated that beta-adrenergic receptor signalling is also disturbed in idiopathic PAH patients, 60 this could be more pronounced in PAH secondary to systemic sclerosis. Increased inflammation could lead to increased expression of prostaglandin E2, which can inhibit intracellular beta-adrenergic receptor signalling by preventing cAMP diffusion to the sarcoplasmic reticulum thereby blocking the beta-adrenergic induced contractile response of cardiomyocytes. 116 This hypothesis is supported by the recent finding of Hsu et al. 105 that the contractile reserve upon exercise in patients with PAH secondary to systemic sclerosis is more impaired than in patients with idiopathic PAH. 112 Future studies should further investigate the contribution of inflammation on the disturbed contractile reserve in patients with systemic sclerosis.
RV fibrosis and RV inflammation
RV fibrosis
There are various techniques available to quantify RV fibrosis in vivo as well as ex vivo. Most often used techniques in PAH-patients is delayed gadolinium enhancement and T1 mapping by magnetic resonance imaging (in vivo) [117] [118] [119] [120] [121] or histomorphometric analyses in cardiac tissue (ex vivo). 21, 122, 123 All studies have reported increased levels of RV fibrosis in PAH-patients. However, with imaging techniques the observed RV fibrosis is often limited to the hinge-points of the RV connected to the interventricular septum, whereas histomorphometric analyses also illustrates increased RV fibrosis in the RV free wall. This discrepancy may be explained by the observation that the RV fibrosis in PAH-patients is not replacement fibrosis but interstitial fibrosis. The latter being more difficult to detect by imaging techniques such as magnetic resonance imaging due to the limited resolution. The functional relevance of the observed increase in RV fibrosis remained elusive until recently. Although the differences between control and PAH RV fibrosis are modest, 21 it is sufficient to explain the impaired RV diastolic stiffness observed in end-stage right heart failure. 124 Besides the amount of RV fibrosis, also the type of RV fibrosis may be relevant. However, currently no data are available on the type of collagen deposition and cross-linking in the RV of PAH-patients with different etiologies. The amount of RV fibrosis has been compared between idiopathic PAH patients and patients with PAH secondary to systemic sclerosis or Eisenmenger. Intriguingly, no difference in RV fibrosis has been observed in idiopathic PAH patients and patients with PAH-secondary to systemic sclerosis, both with in vivo analyses as well as with histomorphometric analyses on RV tissue. 117, 122 This observation was unexpected based on the fact that systemic sclerosis is an auto-immune disease characterized by increased collagen deposition in visceral organs. In line with the similar amount of RV fibrosis between idiopathic PAH-patients and patients with PAH-secondary to systemic sclerosis, also no difference in RV diastolic stiffness has been observed, 97 indicating that the effect of RV pressure overload on RV diastolic function is similar between the two patient groups. A recent post-mortem morphometric analyses by Gomez-Arroyo et al. 123 comparing cardiac tissue of patients with idiopathic PAH, Eisenmenger and control subjects, revealed increased RV fibrosis in both PAH-patient groups. However Eisenmenger patients appeared to have less RV fibrosis than idiopathic PAH-patients, suggesting that RV diastolic function is more preserved in Eisenmenger patients. This hypothesis is further supported by the observation that right atrial pressures are normal in Eisenmenger patients, whereas this is increased idiopathic PAH and PAH secondary to systemic sclerosis ( Figure 3) . From this literature, we can conclude that an adaptive RV phenotype, as is observed in Eisenmenger patients, coincides with less RV fibrosis and RV diastolic impairment. Future therapeutic studies should reveal whether targeting RV fibrosis could be a strategy to prevent the development of right heart failure.
RV inflammation
Little is known about the contribution of RV inflammation on RV adaptation in PAH. From in vitro studies in left heart failure, increased wall stress due to pressure overload results in the secretion of pro-inflammatory cytokines such as tumor necrosis factor alpha by cardiomyocytes. 125, 126 In addition, increased RV inflammatory cell infiltration has been described in an animal model of PAH. 83 We could therefore speculate that impaired adaptation of the RV to the increased load would lead to increased RV wall stress, thereby stimulating RV cardiomyocytes to secrete pro-inflammatory cytokines and attract inflammatory cells. Interestingly, more inflammatory cell infiltration is indeed observed in patients with PAH secondary to systemic sclerosis than in idiopathic PAH-patients, though it is unknown if this is a result of the systemic disease or response to pressure overload. 122, 127 Novel developed tracers for positron emission tomography imaging may enable us to better study these hypotheses, e.g. inflammation can be visualized by a macrophage cell membrane tracer (18 F-FMCH), 128 fibrosis may by visualized by RGD based PET tracers, 129 neurohormonal activity may be visualized by a beta-adrenergic receptor tracer (11 C-CGP12177). 130 Overall, future studies should reveal whether RV inflammation is a contributor to the transition towards right heart failure.
Conclusion
By comparing different PAH etiologies, we could identify three phenotypes of RV adaptation: (i) RV adaptation, as is observed in Eisenmenger patients, which is coincided with RV hypertrophy, RV contractility and low levels of RV fibrosis and RV diastolic stiffness; (ii) RV failure, as is observed in PAH-patients secondary to systemic sclerosis, which is characterized by impaired contractile reserve, increased RV fibrosis and RV diastolic stiffness; (iii) A mixed phenotype, as is observed in patients with idiopathic PAH.
Further in depth comparison of RV hypertrophy development, neurohormonal regulation and RV function between patients with idiopathic PAH, PAH secondary to systemic sclerosis and Eisenmenger patients will enhance our understanding of the different RV adaptation profiles. In addition, progress in new models such as cell culture models or nuclear imaging techniques is of utmost importance to extend our analyses from end-stage heart failure to longitudinal analyses of heart failure development.
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